November 28, 2020

The Niche

Knoepfler lab stem cell blog

J&J stem cells

2 min read

Clinical research on Type I Diabetes is one of the most exciting and promising areas of stem cells and regenerative medicine for human disease. Two of the coolest companies out there in this arena have been ViaCyte and BetaLogics (owned by J&J). For more on ViaCyte see my interview with President and CEO Paul Laikind from 2015. Today brings great news for ViaCyte on two fronts. Incidentally, this gives me a correct prediction on my Top 20 stem cell predictions for 2016. First, it has …Read More

7 min read

It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on their clinical trial, the healthy competition with Doug Melton, and future perspectives. Can you give an update on the VC-01 clinical trial? Answer: We’ve enrolled four patients in the …Read More

2 min read

Big Pharma Giant Johnson & Johnson (J & J; $JNJ) announced today a $12.5 million investment in stem cells & regenerative medicine via the small biotech Capricor ($CAPR) and the potential for the bet to go into the hundreds of millions for the heart disease program. It was only 8 days ago that I made my stem cell predictions for 2014 and #3 on the list was “Big announcement  from “Big Pharma” on stem cells or regenerative medicine.” Chalk that up for the crystal ball of …Read More